NEW YORK (GenomeWeb News) — OncoMethylome Sciences has tapped Rubicon Genomics to identify and analyze biomarkers that may lead to early cancer detection tests, Rubicon said today.
Under the collaboration, Rubicon will use its MethylPlex platform, which identifies multi-gene patterns of abnormal DNA methylation that arise during tumor development, to develop markers that predict the presence of cancer. The agreement also gives OncoMethylome an option to license markers that result from the collaboration.
Rubicon said it has already licensed a set of biomarkers to OncoMethylome resulting from a similar, earlier agreement.
Financial terms of the agreement were not released.